HAE

Business Context and Reporting Period

Company: Haemonetics Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: March 30, 2002
Business Overview: Haemonetics is a market leader in automated systems and single-use disposables for the collection, processing, and surgical salvage of blood. The company operates as a single segment focused on transfusion medicine, serving hospitals, blood banks, and plasma centers in over 50 countries. Key product lines include surgical blood salvage, automated plasma, platelet, and red cell collection, and cell processing systems.

Key Financial Metrics

Revenue Composition: Disposable products accounted for 89.6% of net revenues. Equipment sales represented 5.4%, and service/miscellaneous revenue accounted for 5.1%.

Material Changes vs. Prior Period

• Revenue Growth: Net revenues increased 8.9% year-over-year (13.0% at constant currency). Growth was driven by a 24.8% increase in Plasma disposables, 39.6% in Red Cell disposables, and 10.9% in Surgical disposables (constant currency).
• Profitability Surge: Operating income margin expanded significantly from 4.6% to 11.4%. This was primarily due to a $21.5 million increase in gross profit (constant currency) and a $13.3 million reduction in acquired research and development and unusual charges compared to 2001.
• Acquisition Impact: Fiscal 2001 included $18.6 million in acquired R&D charges and $4.6 million in unusual charges related to the Transfusion Technologies acquisition. Fiscal 2002 included only $10.0 million in acquired R&D (pathogen inactivation technology) and no unusual charges.
• Cash Flow: Operating cash flow decreased by $24.6 million to $32.2 million, largely due to a $18.7 million increase in inventory levels to support higher sales and a $3.4 million increase in accounts receivable.

Guidance, Outlook, and Risks

• Outlook: Management expects Plasma growth to moderate in fiscal 2003 due to slower collection growth and industry consolidation. The company anticipates continued growth in automated red cell collection driven by blood shortages and regulatory changes regarding variant Creutzfeldt-Jakob Disease.
• Strategic Initiatives: The company is integrating pathogen inactivation technology (via alliance with Baxter/Cerus) into platelet collection devices, with European regulatory clearance expected in fiscal 2003. The Chairside Separator system is awaiting FDA approval.
• Stock Repurchase: In February 2002, the Board authorized a program to repurchase up to 1,764,000 shares. The company repurchased 895,800 shares in Q4 2002 for approximately $26.9 million.
• Risks:
  • Customer Concentration: One unaffiliated Japanese customer accounted for 20.0% of total accounts receivable and significant sales volume.
  • Regulatory: Delays in FDA approvals (e.g., American Red Cross software upgrade for double red cell collection) can impact revenue timing.
  • Foreign Exchange: 62% of revenues are generated outside the U.S. A strengthening U.S. dollar negatively impacts reported results; the company uses forward contracts to hedge exposure.

Investor Verification Checklist

• Inventory Levels: Verify the necessity of the $18.7 million increase in inventory against future sales forecasts to ensure no obsolescence risk.
• Customer Concentration: Assess the credit risk and dependency on the single Japanese customer representing 20% of receivables.
• Regulatory Approvals: Monitor the status of the Chairside Separator (CSS) and Red Cell Collector (RCC) FDA approvals, as these are critical for future revenue streams.
• Acquisition Integration: Review the progress of the Fifth Dimension acquisition and the pathogen inactivation technology integration to ensure projected synergies are realized.
• Debt Covenants: Confirm continued compliance with debt covenants, specifically regarding the 7.05% Senior Notes and real estate mortgage.